Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors
Ji-Yeon Lee (Lee JY), Yongin Cho (Cho Y), Minyoung Lee (Lee M), You Jin Kim (Kim YJ), Yong-ho Lee (Lee Yh), Byung-Wan Lee (Lee BW), Bong-Soo Cha (Cha BS), Eun Seok Kang (Kang ES)
Diabetes Metab J. 2019;43(2):158-173.   Published online 2019 Jan 25     DOI: https://doi.org/10.4093/dmj.2018.0057
Citations to this article as recorded by Crossref logo
Effect of Dapagliflozin as an Add-on Therapy to Insulin on the Glycemic Variability in Subjects with Type 2 Diabetes Mellitus (DIVE): A Multicenter, Placebo-Controlled, Double-Blind, Randomized Study
Seung-Hwan Lee, Kyung-Wan Min, Byung-Wan Lee, In-Kyung Jeong, Soon-Jib Yoo, Hyuk-Sang Kwon, Yoon-Hee Choi, Kun-Ho Yoon
Diabetes & Metabolism Journal.2021; 45(3): 339.     CrossRef
Angiotensin II up-regulates sodium-glucose co-transporter 2 expression and SGLT2 inhibitor attenuates Ang II-induced hypertensive renal injury in mice
Kana N. Miyata, Chao-Sheng Lo, Shuiling Zhao, Min-Chun Liao, Yuchao Pang, Shiao-Ying Chang, Junzheng Peng, Matthias Kretzler, Janos G. Filep, Julie R. Ingelfinger, Shao-Ling Zhang, John S.D. Chan
Clinical Science.2021; 135(7): 943.     CrossRef
Sodium-Glucose Cotransporter-2 Inhibitor for Renal Function Preservation in Patients with Type 2 Diabetes Mellitus: A Korean Diabetes Association and Korean Society of Nephrology Consensus Statement
Tae Jung Oh, Ju-Young Moon, Kyu Yeon Hur, Seung Hyun Ko, Hyun Jung Kim, Taehee Kim, Dong Won Lee, Min Kyong Moon
Diabetes & Metabolism Journal.2020; 44(4): 489.     CrossRef
Differential indication for SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with established atherosclerotic heart disease or at risk for congestive heart failure
Francesco Giorgino, Irene Caruso, Julia Moellmann, Michael Lehrke
Metabolism.2020; 104: 154045.     CrossRef
Clinical Predictors of the Hypoglycemic Effect of Sodium–Glucose Co-transporter-2 Inhibitors in Hyperuricemic Patients: A Retrospective Descriptive Observational Study
Toshinori Hirai, Yuya Kawagoe, Motoki Kei, Ryuichi Ogawa, Toshimasa Itoh
Biological and Pharmaceutical Bulletin.2020; 43(5): 782.     CrossRef
Sodium-glucose cotransporter-2 inhibitor for renal function preservation in patients with type 2 diabetes mellitus: A Korean Diabetes Association and Korean Society of Nephrology consensus statement
Tae Jung Oh, Ju-Young Moon, Kyu Yeon Hur, Seung Hyun Ko, Hyun Jung Kim, Taehee Kim, Dong Won Lee, Min Kyong Moon
Kidney Research and Clinical Practice.2020; 39(3): 269.     CrossRef
Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis
Ildiko Lingvay, Matthew S Capehorn, Andrei-Mircea Catarig, Pierre Johansen, Jack Lawson, Anna Sandberg, Robert Shaw, Abby Paine
The Journal of Clinical Endocrinology & Metabolism.2020; 105(12): e4593.     CrossRef
Letter: Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors (Diabetes Metab J 2019;43:158–73)
Kyung-Soo Kim
Diabetes & Metabolism Journal.2019; 43(3): 377.     CrossRef
Response: Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors (Diabetes Metab J 2019;43:158–73)
Ji-Yeon Lee, Eun Seok Kang
Diabetes & Metabolism Journal.2019; 43(3): 379.     CrossRef
An Age of Sodium-Glucose Cotransporter-2 Inhibitor Priority: Are We Ready?
Ji A Seo
Diabetes & Metabolism Journal.2019; 43(5): 578.     CrossRef